Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Majority Of U.S. Residents Support Confirming Supreme Court Nominee Sotomayor, Poll Finds
Sixty-two percent of U.S. residents want Supreme Court nominee Sonia Sotomayor to be confirmed, and 55% say she is "about right" on a liberal-to-conservative scale, according to a recent Washington Post/ABC News poll, the Post reports. For the survey, pollsters randomly surveyed a national sample of 1,001 adults by telephone between June 18 and June 21. The poll has a margin of sampling error of plus or minus three percentage points.The poll found that about three-fourths of abortion-rights supporters want Sotomayor to be confirmed, compared with less than half of abortion-rights opponents. According to the poll, six in 10 U.S. residents would want the new Supreme Court justice to vote to uphold Roe v. Wade. Most Republican men would want the next Supreme Court justice to vote to overturn Roe, while Republican women were split about evenly on the issue, the poll found. The poll also found that support for Sotomayor"s confirmation was equal between men and women. In addition, nearly eight in 10 Democrats and about two-thirds of independents said they supported Sotomayor"s confirmation, compared with 36% of Republicans. The poll found that most Republicans deemed Sotomayor a "more liberal" nominee than they would prefer. Among Republicans, those self-identifying as conservative Republicans were largely opposed to Sotomayor"s confirmation, with more than seven in 10 conservative Republicans saying she is too liberal. Sotomayor received support from Republicans self-identifying as moderate or liberal, with fewer than four in 10 saying she is too liberal. However, about one in five who opposed Sotomayor"s confirmation said that she is not liberal enough. The poll also found that among the 33% of U.S. residents who said that Sotomayor"s gender plays a role, more than twice as many said that is a positive attribute as opposed to a negative attribute (Cohen/Barnes, Washington Post, 6/28).Sessions Requests More InformationSenate Judiciary Committee ranking Republican Jeff Sessions (Ala.) on Friday sent a letter to the White House requesting additional information on Sotomayor, the New York Times" "The Caucus" reports. According to Sessions, the Obama administration has yet to provide members of the committee with information about a number of cases that Sotomayor brought to trial while working as a district attorney in New York. In addition, Sessions requested information regarding a case that Sotomayor argued on appeal. He also requested information about her work with Latino Justice PRLDEF, formerly known as the Puerto Rican Legal Defense and Education Fund. Sotomayor"s confirmation hearing is scheduled to begin July 13. Republicans have criticized the schedule, saying it gives them insufficient time to review Sotomayor"s record. Democrats have said that Republicans are seeking to create unnecessary delays and noted that the timeline is similar to that of past nominees (Herszenhorn, "The Caucus," New York Times, 6/26).
generic viagra online
Move From Daily To Weekly Welsh Assembly Government Swine Flu Reports, Wales
On 2 July, based on scientific advice, the UK moved to a new "treatment" phase in our response to the current swine flu pandemic.
News of the day
Study Demonstrates Internet Risks For Teen Girls
A new study demonstrates why parents need to know how their teenage girls present themselves online.
Public Health

BioLineRx Announces Positive Preliminary Results From The Phase I/II Trial Of BL-1040

BioLineRx Ltd. (TASE:BLRX), a clinical stage drug development company, today announced positive preliminary results from the ongoing phase I/II clinical trial designed to assess the safety and feasibility of BL-1040, the first injectable device designed to address cardiac remodeling, in 20- 30 patients at several sites in Germany and Belgium. To date, 15 patients were successfully treated with BL-1040 with no complications. Moreover, six months follow up results from the first 5 patients show BL-1040"s efficacy in preventing cardiac remodeling and preserving cardiac function. BL-1040 represents a breakthrough approach to supporting cardiac tissue damaged as a result of acute myocardial infarction (MI), improving cardiac function and survival. BL-1040 is a resorbable liquid polymer that is administered via the coronary artery during standard catheterization and flows into the damaged heart muscle. BL-1040 undergoes a liquid to gel phase transition within the infarcted cardiac tissue and forms a protective "scaffold" that enhances the mechanical strength of the heart muscle during recovery and repair, thereby preventing pathological enlargement of the left ventricle after the MI. BL-1040 is excreted naturally from the body within six weeks after injection, leaving behind a stronger, more stable heart muscle. The safety, biocompatibility and efficacy of BL-1040 were demonstrated in pre-clinical studies performed in multiple species. BL-1040 was shown to prevent wall thinning and stabilize End Systolic Volume (ESV) and Ejection Fraction (EF). Data from the ongoing phase I/II trial confirm these findings. To date, 15 patients suffering from a significant infarction were successfully treated with BL-1040 with no complications, no arrhythmias, no elevations in cardiac enzymes and no occlusions. In addition, six months follow up data from the first 5 patients show that BL-1040 prevented End Systolic and End Diastolic Volume dilation, prevented wall thinning and preserved left ventricular dimensions. It is important to note, that patients enrolled in the study suffered a significant MI and were expected to display wall thinning and volume dilations. "BL-1040 could revolutionize the treatment of patients recovering from a massive heart attack," said Professor Jonathan Leor, Director of the Neufeld Cardiac Research Institute at Tel-Aviv University, Israel who invented BL-1040 and conducted the initial experiments together with Professor Smadar Cohen from Ben Gurion University, Israel. "We look forward to completing the trial and believe that it will continue to provide more evidence for the success of our new approach to bring effective and safe treatment for patients with injured hearts," added Professor Leor. "This is an important milestone in the development of BL-1040, BioLineRx"s innovative product candidate, which is the first treatment that attempts to treat damaged cardiac tissue resulting from an acute MI and addresses a tremendous unmet medical need," said Morris C. Laster, MD, CEO of BioLineRx. BL-1040 was in-licensed by BioLineRx from Ben-Gurion University through BGN Technologies, and it was developed by Professor Smadar Cohen and Professor Jonathan Leor from Tel Aviv University. For further information on BL-1040, please visit the BioLineRx website and BL-1040 animation at http://www.biolinerx.com/PipelineSelected.asp About Acute Myocardial Infarction Acute MI is a leading cause of morbidity and mortality in the Western world. Approximately 1.3 million cases of nonfatal MI are reported each year in the U.S. alone, with an annual incidence rate of approximately 600 cases per 100,000 people. BioLineRx


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009